Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New combo aims to tame lymphoma with less radiation damage

NCT ID NCT07554898

First seen Apr 30, 2026 · Last updated Apr 30, 2026 · Updated 1 time

Summary

This study tests a two-step treatment for adults with early-stage MALT lymphoma: a very low dose of radiation (4 Gy total) followed by a daily targeted pill (orelabrutinib) for up to 6 months. The goal is to control the cancer while avoiding harsh side effects like dry mouth or cataracts that standard radiation can cause. About 60 participants will be followed for at least 3 months to see how well the cancer responds and how safe the treatment is.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALT LYMPHOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • No. 1, East Banshan Road , Gongshu District

    RECRUITING

    Hangzhou, Zhejiang, 310000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    RECRUITING

    Hangzhou, Zhejiang, 310000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.